SCHEMBL735105

SCHEMBL735105

COC(=O)C(CCOCc1ccccc1)N1CCN(c2ccc(Cl)c(Cl)c2)CCC1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.46
MAPT P10636 7/20 0.46
ALDH1A1 P00352 4/20 0.46
GAA P10253 2/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
HTT P42858 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
RECQL P46063 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.41
GRM5 P41594 2/20 0.40
TACR1 P25103 2/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
CCR1 P32246 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735104 1.00 LMNA (0.46) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL734793 0.90 GRM5 (0.52) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL734794 0.90 GRM5 (0.52) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL734338 0.85 LMNA (0.42) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL734339 0.85 LMNA (0.42) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL734611 0.84 MAPT (0.47) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL734612 0.84 MAPT (0.47) LMNAMAPTALDH1A1GAASMN1; SMN2
SCHEMBL735610 0.84 MAPT (0.50) LMNAMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL735609 0.84 MAPT (0.50) LMNAMAPTALDH1A1SMN1; SMN2HTT
SCHEMBL734350 0.84 HSD17B10 (0.47) LMNAMAPTALDH1A1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138175-B2 Heterocyclyl compounds HOFFMANN-LA ROCHE INC. (US) 2012-03-20 US disclosed
EP-2321285-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2011-05-18 EP disclosed
WO-2010012619-A1 DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2010-02-04 WO disclosed
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022518-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR5 LMNA 3760/4885MAPT 4751/4885ALDH1A1 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.